Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

61.69 -1.38 (-2.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,794,843
Open 63.16
Bid (Size) 61.70 (9)
Ask (Size) 62.02 (1)
Prev. Close 63.07
Today's Range 61.61 - 63.58
52wk Range 57.16 - 74.12
Shares Outstanding 1,253,809,440
Dividend Yield 4.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Biotech Stocks to Sell in October
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
Via InvestorPlace
Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29
Reuters 
Via Benzinga

Performance

YTD
-15.00%
-15.00%
1 Month
-5.02%
-5.02%
3 Month
-1.04%
-1.04%
6 Month
+1.68%
+1.68%
1 Year
-10.02%
-10.02%

More News

Read More
Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
Via Benzinga
7 Monthly Dividend Stocks to Buy for Safety
Via InvestorPlace
WHO Recommends Gilead's COVID-19 Therapy For Severe Disease
Via Benzinga
Why Is Gilead Sciences (GILD) Stock Up Today?
Via InvestorPlace
Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
Via Benzinga
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
Via InvestorPlace
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Completes Acquisition of MiroBio
From Gilead Sciences, Inc.
Via Business Wire
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Via Benzinga
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Via Benzinga
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
Via Benzinga
7 Penny Stocks That Actually Have a Buy Rating
Via InvestorPlace
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says
Via Benzinga
Taking Charge of Your Care This Blood Cancer Awareness Month
Via Brandpoint
Topics Death
Exposures Death
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
Via Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
Via Benzinga
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
From Gilead Sciences, Inc.
Via Business Wire
Why HIV Testing Should Be an Important and Normal Part of Your Self-Care Routine
Via Brandpoint
Exposures COVID-19
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.